Healthy Clinical Trial
— PRO-TrainingOfficial title:
Efficacy and Cost-effectiveness of Supervised Center-based Versus Unsupervised Home-based Training Programs in Older Adults: the PRO-Training Randomized Controlled Trial
The superiority of supervised center-based training programs compared with unsupervised home-based ones in older adults remains unclear, and no evidence exists on whether including a motivational component could moderate these differences. The present randomized controlled trial aims to determine the role of supervision and motivational strategies on the safety, adherence, efficacy, and cost-effectiveness of different training programs for improving physical and mental health in older adults. Participants (n=120, aged 60-75 years old) will be randomly divided into five groups: 1- Control group, 2- Unsupervised home-based exercise group without motivational intervention (UNSUP), 3- Unsupervised home-based exercise group with motivational intervention (UNSUP+), 4- Supervised center-based exercise group without motivational intervention (SUP) and 5- Supervised center-based exercise group with motivational intervention (SUP+). Participants assigned to the exercise groups will participate in a 24-week multicomponent exercise program (3 sessions/week, 60 min/session), while participants in the control group will be asked to maintain their usual lifestyle. Physical and mental health outcomes will be assessed, including lower and upper-body muscular function, physical function, cardiorespiratory function, anthropometry and body composition, health-related quality of life, cognitive performance, anxiety and depression status, physical activity and sedentary behavior, sleep, biochemical markers, motivators and barriers to exercise, individual's psychological needs, and level of self-determination. Assessments will be conducted at baseline (week 0), mid-intervention (week 12), at the end of the intervention period (week 25), and 24 weeks after the exercise intervention (week 48).
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 20, 2024 |
Est. primary completion date | July 19, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 75 Years |
Eligibility | Inclusion Criteria: - People aged between 60 and 75 years old. - Being able to speak and read fluent Spanish. - Being able to walk independently. - Being physically able to participate in an exercise program. - Having a smartphone and being able to understand and use mobile applications autonomously. Exclusion Criteria: - Acute or terminal illness. - Myocardial infarction, coronary artery bypass grafting, angioplasty, angina, or other cardiac condition in the past year. - Uncontrolled medical problems that the general practitioner considers would preclude patients from undertaking the exercise program (e.g., acute systemic illness such as pneumonia, acute rheumatoid arthritis, and acute or unstable heart failure). - Conditions requiring a specialized physical exercise program (e.g., uncontrolled epilepsy, significant neurological disease or impairment, inability to maintain an upright seated position or unable to move independently, multiple sclerosis, cancer, Parkinson's, Alzheimer's, or chronic obstructive pulmonary disease). - General practitioner-diagnosed hypertension that has not been controlled. - Type I Diabetes or uncontrolled Type II Diabetes. - History of major psychiatric illness including schizophrenia, generalized anxiety disorder, or depression according to the DSM-5. - Morbid obesity (body mass index >39) - Three or more self-reported falls in the last year. - Not living in the community (e.g., living in nursing homes). - Having participated in an exercise program during the 6 months prior to the study. - Diagnosis of COVID-19 with hospitalization in intensive care unit. - Any other consideration that interferes with the study aims and could be a risk to the participant, at the discretion of the researcher and the general practitioner. |
Country | Name | City | State |
---|---|---|---|
Spain | University of Castilla-La Mancha | Toledo | Castilla-La Mancha/Toledo |
Lead Sponsor | Collaborator |
---|---|
University of Castilla-La Mancha | Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES), Complejo Hospitalario de Toledo |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Lower-body muscular function | The force-velocity relationship and the rate of force development (RFD) will be assessed on a horizontal leg press device (Technogym, Element, Italy) instrumented with a force plate (Type 9286BA, Kistler, Switzerland) and a linear position transducer device (TForce System, Ergotech, Spain). A familiarization session will be performed in session one before the evaluation day in session number three. | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Primary | Costs | Researchers will calculate total costs and costs per participant for each of the intervention groups. Mean difference in quality-adjusted life-year (QALY) scores at the end of the intervention will be assessed to analyze the cost-utility. Furthermore, an incremental cost-effectiveness ratio (ICER) will be assessed. Data on health-related quality of life measured by EQ-5D will be used for the calculations. | Through intervention completion, that is 24 weeks. | |
Primary | Adherence to physical training program | Adherence to physical training program will be recorded in the unsupervised training groups using the mobile app. Trainers will record adherence to physical training program in the supervised training groups. It will be calculated as a percentage ([sessions completed/total sessions expected] x 100), where 0 % indicates total non-adherence and 100 % indicates full adherence to the exercise prescription. During the 24-week follow-up, we will assess through an ad-hoc self-reported questionnaire whether or not participants exercised, the exercise modality performed (supervised center-based and/or unsupervised home-based), and the number of weekly exercise sessions performed. The questionnaire will be administered on a weekly basis in written form. | Through study completion, that is 48 weeks. | |
Primary | Falls and adverse events | Participants in the unsupervised and control groups will record in a diary their falls and adverse events during and outside exercise sessions. In the supervised groups, supervisors will register the incidence of falls during exercise sessions and participants will register them outside the exercise sessions using the diary. | Through intervention completion, that is 24 weeks. | |
Secondary | Upper-body muscular function | Grip strength will be measured with a standard hydraulic hand-held dynamometer on both arms (Takei TKK5401, Tokyo, Japan). | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Maximum walking speed (10-m) | Time the participant takes to walk 10 meters at maximum speed without running. | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Usual walking speed (3, 6 and 10-m) | Time the participant spends walking 3, 6 and 10 meters at their usual pace. | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Short Physical Performance Battery (SPPB) | To assess the ability to stand with feet together in side-to-side, semi-tandem, and tandem positions (balance), 4-meters walk test (speed), and 5 times sit-to-stand (muscle power). | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Senior Fitness Test (SFT) | SFT battery includes 30-second chair stand test (lower-body strength), 30-second arm curl test (upper-body strength), 6-minute walk test (aerobic endurance), Chair sit-and-reach test (lower-body flexibility), Back scratch test (upper-body flexibility) and 8-foot up-and-go test (agility and dynamic balance). | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Cardiorespiratory function | Cardiorespiratory function will be assessed by a maximal incremental cycloergometer test using a gas analyzer (Cosmed QUARK, Italy). An electrocardiogram will be performed both at rest and during exercise to evaluate the electrical activity of the heart. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Blood pressure | Systolic and diastolic blood pressure and heart rate will be assessed at rest using a digital upper arm blood pressure monitor (OMRON M2, Spain). | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Anthropometry | Height and body mass will be measured with a stadiometer and scale (Seca 711, Hamburg, Germany) without shoes to the nearest 0.1 cm and 0.1 kg, respectively, and body mass index will be calculated. In addition, the perimeters of the neck, waist, and hip will be measured. | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Body composition | Four bone densitometry tests will be performed on each subject (whole body, forearm, lumbar spine, and femoral neck) using bone densitometry (Hologic Series Horizon-A, Bedford, United States). For the determination of muscle, fat, and bone mass, the results of the whole-body test will be used. For regional analysis, values from all tests will be used. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Health-related quality of life | The EuroQol-5D questionnaire will be used for assessing the health status of the participants, including a descriptive system formed by five dimensions and a visual analogue scale. | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Cognitive Performance | The Trail-Making Test Part A and B, the Montreal Cognitive Assessment (MoCA) and the Digital Symbol Substitution test will be administered in the cognitive evaluation. | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Anxiety | The Zung Anxiety Self-Assessment Scale will be used. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Depression | The short form of the Yesavage Geriatric Depression Scale will be used. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Physical activity and sedentary behavior patterns | Physical activity and sedentary behavior will be assessed by accelerometry (GeneActiv Original, Activinsights, UK). The devices will be placed on the subject's non-dominant wrist using a watch strap for 8 days. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Sleep | The number of hours of sleep will be assessed by accelerometry (GeneActiv Original, Activinsights, UK). In addition, the Pittsburgh Sleep Quality Index will be used as an additional instrument. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Biochemical markers | Blood samples will be collected at rest after an overnight fast (>12 h). Samples will be collected at least 72-96 h apart from any exercise or testing session. Samples will be analyzed immediately for routine clinical chemistry measurements and then, they will be put into 500-µL aliquots and frozen at -80ºC for later analysis. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Motivators and barriers to exercise | Motivators and barriers to exercise will be measured using the Exercise Benefits/Barriers Scale. | Baseline (week 0), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Motivation to exercise according to self-determination theory | For the evaluation of motivation according to the self-determination theory, the Behavioral Regulation during Exercise Questionnaire (BREQ-3) will be used. | Baseline (week 0), mid-intervention (week 12), post-intervention (week 25), and follow-up (week 48). | |
Secondary | Basic Psychological Needs in Exercise | The Basic Psychological Needs in Exercise Scale (BPNES) will be used to assess the satisfaction of the three needs autonomy, competence, and relatedness in the exercise domain. | Post-intervention (week 25) and follow-up (week 48). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |